Ahead of eyeforpharma Philadelphia 2019, Sonal Bhatia, Pfizer’s vice president, North America medical lead, rare disease talked to us about the importance of collaboration and RWE to he
Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 immuno
Bayer has filed its prostate cancer drug darolutamide with Japanese regulators, in an attempt to ratchet up the pressure on rivals Johnson & Johnson and Pfizer/Astellas.
Pfizer and Eli Lilly have announced more positive results from a phase 3 study of their non-opioid pain drug tanezumab, this time in chronic lower back pain (CBLP).